Medpace Holdings, Inc. $MEDP Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 27.5% in the second quarter, Holdings Channel reports. The firm owned 14,476 shares of the company’s stock after selling 5,478 shares during the period. WINTON GROUP Ltd’s holdings in Medpace were worth $4,543,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of MEDP. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Employees Retirement System of Texas purchased a new position in Medpace in the 2nd quarter worth $36,000. IFP Advisors Inc lifted its position in Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares during the period. Finally, Hantz Financial Services Inc. grew its stake in Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. BMO Capital Markets began coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. TD Cowen raised their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Truist Financial set a $555.00 price objective on shares of Medpace in a report on Monday, October 27th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Mizuho lifted their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $487.18.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 387,925 shares of company stock worth $233,386,647 over the last ninety days. Company insiders own 20.30% of the company’s stock.

Medpace Trading Up 0.6%

NASDAQ MEDP opened at $548.12 on Monday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26. The stock has a market cap of $15.44 billion, a PE ratio of 38.33, a P/E/G ratio of 2.06 and a beta of 1.43. The stock has a fifty day simple moving average of $567.90 and a 200-day simple moving average of $454.82.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.